Palbociclib CAS 571190-30-2 Puritas >99.5% (HPLC) API Factory

Description:

Nomen chemicum: Palbociclib

CAS: 571190-30-2

Puritas: >99.5% (HPLC)

Aspectus: Alba vel Off-White pulveris

API Curatio Cancri

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Palbociclib Intermedia:
Palbociclib CAS 571190-30-2
5-Bromo-2,4-Dichloropyrimidines CAS 36082-50-5
5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8
tert-Butyl 4-(6-Nitropyridin-3-yl) piperazine-1-Carboxylate CAS 571189-16-7
tert-Butyl 4-(6-Amino-3-pyridyl) piperazine-1-Carboxylate CAS 571188-59-5
6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2
2-Chloro-8-Cyclopentyl-5-Methyl-8H-pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4

Chemical Properties:

Nomen chemicum	Palbociclib
Synonyma	PD-0332991;Otava-Bb 1115529;Ibrance
CAS Number	571190-30-2
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C24H29N7O2
M. Pondus	447.54
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba vel Off-White pulveris
1H NMR Imaginum	Congruunt cum Structure
HPLC	Congruunt cum Structure
Substantiae cognatae
Individual Impurity	<0.50%
Totalis immunditias	<1.00%
Damnum in Siccatio	<0.50%
Residere in Ignition	<0.10%
Metalla gravis	<10ppm
Puritas / Analysis Methodus	>99.5% (HPLC)
Test Standard	Enterprise Standard
Consuetudinem	API, De curatione Cancri

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

Palbociclib (CAS: 571190-30-2) ore promptum est kinasum cyclinum-dependens (CDK) inhibitor cum actione antineoplastica potentiale.Palbociclib selective vetat cyclino-dependens kinasum 4 (CDK4) et 6 (CDK6), inde inhibuit retinoblastoma (Rb) interdum phosphorylationem mane in G1 periodo ducens ad cyclum cellulam comprehensionem.Haec DNA replicationem supprimit et multiplicationem cellae tumoris decrescit.Palbociclib primus est repraesentativus novi generis medicamentorum cyclin-dependens inhibitores kinasi.Hic effectus terminat prolificationem cellulae (Cellae incrementum et divisionem).Ponitur pro agente antineoplastico in cancer provectus vel metastaticus pectoris.